Botox's Third Ingredient Just Pulled It Off Medicare's Negotiating Table
A judge ruled that human serum albumin, a plasma-derived ingredient in Botox since 1989, puts the drug outside Medicare's price negotiation program, 13 days before CMS must publish 2028 prices.
Botox should never have been on Medicare's negotiating table, a federal judge ruled on Oct 29, because one of its three ingredients comes from human plasma. It is the first time a drugmaker has used a statutory exclusion to get a product out of the negotiation program, and it leaves CMS 13 days before its Nov 30 deadline to publish the prices it negotiated for 15 drugs, Botox among them.
Botox was one of five drugs in the third cycle, alongside Orencia, Entyvio, Xolair and Cimzia, whose Medicare spending runs mostly through Part B, a side of the program this cycle brought into negotiation for the first time.
The albumin reading
The Inflation Reduction Act excludes from the definition of a qualifying single source drug, and therefore from negotiation, any biological product derived from human whole blood or plasma. The government read that carve-out narrowly, applying it only when a product's active ingredient comes from plasma. Botox's active ingredient, onabotulinumtoxinA, is a protein toxin rather than a blood product, so CMS selected the drug for negotiation. AbbVie argued the exclusion looks at the product as a whole.
Judge Carl J. Nichols agreed. In his opinion in AbbVie Inc. v. U.S. Department of Health and Human Services, Civil Action No. 1:26-cv-00431 (CJN), he noted that Botox has carried the same three ingredients since the FDA licensed it in 1989: onabotulinumtoxinA, sodium chloride, and human serum albumin, a protein obtained from human plasma that keeps the toxin from breaking down and clumping. By mass, each vial holds roughly 100,000 times more albumin than active toxin. Without the albumin, the court noted, the product cannot be made. Botox, as an aggregated biological product, is therefore derived from human plasma and subject to exclusion.
CMS's reading also made the exclusion nearly pointless. The government estimated at oral argument that only a dozen or so biological products would fall inside it, none of them a significant Medicare expense. The court said it was not obvious why Congress would write one of only three statutory exclusions for so small and inexpensive a set.
The government warned that manufacturers could add a plasma-derived ingredient to dodge negotiation, and that mixed formulations would be hard to administer. The court noted that Botox has carried albumin in every form since 1989, that AbbVie offered unrebutted evidence that plasma makes manufacturing harder rather than easier, and that the FDA must approve major changes to a licensed product, including to inactive ingredients.
The court granted AbbVie's motion for summary judgment in part and denied the government's in part, stopping at the statutory question. AbbVie's constitutional and ultra vires claims were not reached.
A first, on narrow ground
Other manufacturers have challenged the program and lost. In August the D.C. Circuit's decision in Teva Pharmaceuticals USA, Inc. v. Kennedy upheld CMS's authority to treat drugs with the same active ingredient and manufacturer as one qualifying single source drug across separate FDA applications, and rejected Teva's due process claim. It held that CMS's bona fide marketing standard for generics is ripe for review, leaving its lawfulness open, and confirmed that courts may review the agency's general interpretations. The government has asked the full court to rehear the case, in a petition filed Oct 2; Teva responded Oct 30.
AbbVie's win is the first by a drugmaker on a statutory exclusion rather than a constitutional theory. It rests on text, which makes it portable: manufacturers of selected biologics now have a reason to audit their inactive ingredients.
The clock
Negotiations in the third cycle closed on Nov 1, and under the statute CMS must publish the resulting maximum fair prices no later than Nov 30, two years before they take effect on Jan 1, 2028. The 15 selected drugs, announced on Jan 27, 2026, accounted for about $27 billion in combined Part B and Part D spending and roughly 1.8 million beneficiaries, about 6% of combined program spending.
Botox, including Botox Cosmetic, accounted for $1,143,070,000 in combined Part B and Part D spending from November 2024 through October 2025, used by 390,000 enrollees, per the CMS fact sheet for the cycle. Whether CMS publishes a price anyway, treats the drug as excluded, or appeals is not yet clear.
A rule built for a different problem
Less than two weeks after the ruling, CMS published a final rule that hardens the program. Issued as 91 FR 72176 on Nov 9 and effective Dec 5, it codifies negotiation and finalizes a policy for new fixed-combination formulations from 2029, aimed at manufacturers who steer patients to reformulated versions to escape a negotiated price. It also sets a temporary price floor for certain small biotech drugs in 2029 and 2030, codifies two Part D policies, and fixes Feb 1, 2027 for selecting up to 20 drugs for the fourth cycle.
That rule closes a loophole requiring a new formulation. The Botox ruling opens one requiring none at all: the ingredient has been in the vial since 1989. CMS can write rules faster than Congress can rewrite a statute, and the exclusion the court applied is Congress's language.